Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model
- Autores
- Marin, Gustavo Horacio; Medrano, L.; Marin, Gustavo Horacio; Rolla, J. B.; Marin, L.; Carlson, S.; Martínez, F.; Nelson, A.
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: To measure vaccination`s risks it exists the term “events supposedly attributed to vaccination or immunization”(ESAVI). ESAVI monitoring usually consist in passive surveillance based on voluntary notifications done either by beneficiariesor by health professionals. The spontaneous reports are scarce compared with active surveillance. Unfortunately; activemethods performed by health service are expensive, laborious and unfeasible due to the few health personnel available.Objective: to evaluate the efficacy of an active method for ESAVI reports associated to COVID19- vaccines performed byuniversity students.Methods: a research comparing two Pharmacovigilance methods for COVID-19-ESAVI was performed (passive vs activesurveillance with participation of university students) from May to September 2021.Results: At the end of the study period, in Argentina 52.786.324 anti-COVID-19 vaccines were applied (1st dose 56, 86%; 2nddose 43, 14%), and 102.358 ESAVIs were validated (1st dose 74, 75%; 2nd dose 23, 96%; other dose 0, 5%; No data 1, 24); 2,16% among them were considered severe. Although female/male vaccination/ratio was similar (50.31% vs 49.67%), ESAVIwere much more reported by females (72.8%). The active pharmacovigilance experience was performed by 933 students-volunteers. They contacted 56,824 vaccinated people; obtaining 39,952 “positive” calls (either “no events” or “potential ESAVI”results). The monthly contacts performed by students were 14,206±1124; among them, 1186±436 calls were “refused”, whilein 3,032±741 cases existed wrong phone number. From 6.652 potential ESAVI reported; 1,037 were validated, which means1.82% of vaccinated people contacted, certainly a better result than the 0.121%obtained by passive reports (p <0.0001).Conclusion: An active method of pharmacovigilance performed by health students was able to increase 15 times the validatedESAVI reports after COVID-19 vaccination.
Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
Fil: Medrano, L.. No especifíca;
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina
Fil: Rolla, J. B.. No especifíca;
Fil: Marin, L.. No especifíca;
Fil: Carlson, S.. No especifíca;
Fil: Martínez, F.. No especifíca;
Fil: Nelson, A.. No especifíca; - Materia
-
COVID-19
Vaccines
ESAVI - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/241054
Ver los metadatos del registro completo
id |
CONICETDig_fbf9d255ebf5e20095ee378c405c9fc4 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/241054 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance ModelMarin, Gustavo HoracioMedrano, L.Marin, Gustavo HoracioRolla, J. B.Marin, L.Carlson, S.Martínez, F.Nelson, A.COVID-19VaccinesESAVIhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Background: To measure vaccination`s risks it exists the term “events supposedly attributed to vaccination or immunization”(ESAVI). ESAVI monitoring usually consist in passive surveillance based on voluntary notifications done either by beneficiariesor by health professionals. The spontaneous reports are scarce compared with active surveillance. Unfortunately; activemethods performed by health service are expensive, laborious and unfeasible due to the few health personnel available.Objective: to evaluate the efficacy of an active method for ESAVI reports associated to COVID19- vaccines performed byuniversity students.Methods: a research comparing two Pharmacovigilance methods for COVID-19-ESAVI was performed (passive vs activesurveillance with participation of university students) from May to September 2021.Results: At the end of the study period, in Argentina 52.786.324 anti-COVID-19 vaccines were applied (1st dose 56, 86%; 2nddose 43, 14%), and 102.358 ESAVIs were validated (1st dose 74, 75%; 2nd dose 23, 96%; other dose 0, 5%; No data 1, 24); 2,16% among them were considered severe. Although female/male vaccination/ratio was similar (50.31% vs 49.67%), ESAVIwere much more reported by females (72.8%). The active pharmacovigilance experience was performed by 933 students-volunteers. They contacted 56,824 vaccinated people; obtaining 39,952 “positive” calls (either “no events” or “potential ESAVI”results). The monthly contacts performed by students were 14,206±1124; among them, 1186±436 calls were “refused”, whilein 3,032±741 cases existed wrong phone number. From 6.652 potential ESAVI reported; 1,037 were validated, which means1.82% of vaccinated people contacted, certainly a better result than the 0.121%obtained by passive reports (p <0.0001).Conclusion: An active method of pharmacovigilance performed by health students was able to increase 15 times the validatedESAVI reports after COVID-19 vaccination.Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaFil: Medrano, L.. No especifíca;Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; ArgentinaFil: Rolla, J. B.. No especifíca;Fil: Marin, L.. No especifíca;Fil: Carlson, S.. No especifíca;Fil: Martínez, F.. No especifíca;Fil: Nelson, A.. No especifíca;MedWin Publishers2022-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/241054Marin, Gustavo Horacio; Medrano, L.; Marin, Gustavo Horacio; Rolla, J. B.; Marin, L.; et al.; Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model; MedWin Publishers; Epidemiology International Journal; 6; 1; 2-2022; 225-2292639-2038CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://medwinpublishers.com/EIJ/covid-19-vaccination-advantages-of-opting-for-an-active-pharmacovigilance-model.pdfinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:55:21Zoai:ri.conicet.gov.ar:11336/241054instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:55:21.96CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model |
title |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model |
spellingShingle |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model Marin, Gustavo Horacio COVID-19 Vaccines ESAVI |
title_short |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model |
title_full |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model |
title_fullStr |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model |
title_full_unstemmed |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model |
title_sort |
Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model |
dc.creator.none.fl_str_mv |
Marin, Gustavo Horacio Medrano, L. Marin, Gustavo Horacio Rolla, J. B. Marin, L. Carlson, S. Martínez, F. Nelson, A. |
author |
Marin, Gustavo Horacio |
author_facet |
Marin, Gustavo Horacio Medrano, L. Rolla, J. B. Marin, L. Carlson, S. Martínez, F. Nelson, A. |
author_role |
author |
author2 |
Medrano, L. Rolla, J. B. Marin, L. Carlson, S. Martínez, F. Nelson, A. |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
COVID-19 Vaccines ESAVI |
topic |
COVID-19 Vaccines ESAVI |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Background: To measure vaccination`s risks it exists the term “events supposedly attributed to vaccination or immunization”(ESAVI). ESAVI monitoring usually consist in passive surveillance based on voluntary notifications done either by beneficiariesor by health professionals. The spontaneous reports are scarce compared with active surveillance. Unfortunately; activemethods performed by health service are expensive, laborious and unfeasible due to the few health personnel available.Objective: to evaluate the efficacy of an active method for ESAVI reports associated to COVID19- vaccines performed byuniversity students.Methods: a research comparing two Pharmacovigilance methods for COVID-19-ESAVI was performed (passive vs activesurveillance with participation of university students) from May to September 2021.Results: At the end of the study period, in Argentina 52.786.324 anti-COVID-19 vaccines were applied (1st dose 56, 86%; 2nddose 43, 14%), and 102.358 ESAVIs were validated (1st dose 74, 75%; 2nd dose 23, 96%; other dose 0, 5%; No data 1, 24); 2,16% among them were considered severe. Although female/male vaccination/ratio was similar (50.31% vs 49.67%), ESAVIwere much more reported by females (72.8%). The active pharmacovigilance experience was performed by 933 students-volunteers. They contacted 56,824 vaccinated people; obtaining 39,952 “positive” calls (either “no events” or “potential ESAVI”results). The monthly contacts performed by students were 14,206±1124; among them, 1186±436 calls were “refused”, whilein 3,032±741 cases existed wrong phone number. From 6.652 potential ESAVI reported; 1,037 were validated, which means1.82% of vaccinated people contacted, certainly a better result than the 0.121%obtained by passive reports (p <0.0001).Conclusion: An active method of pharmacovigilance performed by health students was able to increase 15 times the validatedESAVI reports after COVID-19 vaccination. Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina Fil: Medrano, L.. No especifíca; Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina Fil: Rolla, J. B.. No especifíca; Fil: Marin, L.. No especifíca; Fil: Carlson, S.. No especifíca; Fil: Martínez, F.. No especifíca; Fil: Nelson, A.. No especifíca; |
description |
Background: To measure vaccination`s risks it exists the term “events supposedly attributed to vaccination or immunization”(ESAVI). ESAVI monitoring usually consist in passive surveillance based on voluntary notifications done either by beneficiariesor by health professionals. The spontaneous reports are scarce compared with active surveillance. Unfortunately; activemethods performed by health service are expensive, laborious and unfeasible due to the few health personnel available.Objective: to evaluate the efficacy of an active method for ESAVI reports associated to COVID19- vaccines performed byuniversity students.Methods: a research comparing two Pharmacovigilance methods for COVID-19-ESAVI was performed (passive vs activesurveillance with participation of university students) from May to September 2021.Results: At the end of the study period, in Argentina 52.786.324 anti-COVID-19 vaccines were applied (1st dose 56, 86%; 2nddose 43, 14%), and 102.358 ESAVIs were validated (1st dose 74, 75%; 2nd dose 23, 96%; other dose 0, 5%; No data 1, 24); 2,16% among them were considered severe. Although female/male vaccination/ratio was similar (50.31% vs 49.67%), ESAVIwere much more reported by females (72.8%). The active pharmacovigilance experience was performed by 933 students-volunteers. They contacted 56,824 vaccinated people; obtaining 39,952 “positive” calls (either “no events” or “potential ESAVI”results). The monthly contacts performed by students were 14,206±1124; among them, 1186±436 calls were “refused”, whilein 3,032±741 cases existed wrong phone number. From 6.652 potential ESAVI reported; 1,037 were validated, which means1.82% of vaccinated people contacted, certainly a better result than the 0.121%obtained by passive reports (p <0.0001).Conclusion: An active method of pharmacovigilance performed by health students was able to increase 15 times the validatedESAVI reports after COVID-19 vaccination. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-02 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/241054 Marin, Gustavo Horacio; Medrano, L.; Marin, Gustavo Horacio; Rolla, J. B.; Marin, L.; et al.; Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model; MedWin Publishers; Epidemiology International Journal; 6; 1; 2-2022; 225-229 2639-2038 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/241054 |
identifier_str_mv |
Marin, Gustavo Horacio; Medrano, L.; Marin, Gustavo Horacio; Rolla, J. B.; Marin, L.; et al.; Covid-19 Vaccination Advantages of Opting for an Active Pharmacovigilance Model; MedWin Publishers; Epidemiology International Journal; 6; 1; 2-2022; 225-229 2639-2038 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://medwinpublishers.com/EIJ/covid-19-vaccination-advantages-of-opting-for-an-active-pharmacovigilance-model.pdf |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
MedWin Publishers |
publisher.none.fl_str_mv |
MedWin Publishers |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613669477941248 |
score |
13.070432 |